Skip to main content

Table 4 Effect of tolvaptan at baseline and during inhibition of the nitric oxide system on plasma concentrations of renin(PRC), angiotensin II (P-AngII), aldosterone (P-aldo) and vasopressin (P-AVP) in a randomized, placebo-controlled, double-blind, crossover study of 19 healthy subjects

From: Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects

Periods Baseline L-NMMA Post infusion P (GLM-within)
11:00 AM 12:00 AM 1:00 PM
PRC(pg/ml)
Placebo 8.1 ± 4.3 6.1 ± 3.2** 5.9 ± 3.2** 0.670
Tolvaptan 9.9 ± 6.8 7.5 ± 4.6** 7.5 ± 5.4**
p (GLM between) 0.305
p (paired t-test, between) 0.101 0.050 0.038  
P-AngII (pg/ml)
Placebo 9.5 ± 4 8.6 ± 3.7 8.0 ± 3.3* 0.156
Tolvaptan 11.9 ± 6.2 9.4 ± 4.6* 9.5 ± 5.1*
p (GLM between) 0.686
p (paired t-test, between) 0.094 0.403 0.117  
P- Aldo (pmol/L)
Placebo 70 ± 2 75 ± 2 64 ± 2 0.949
Tolvaptan 71 ± 2 78 ± 2 66 ± 1
p (GLM between) 0.899
p (paired t-test, between) 0.962 0.785 0.840  
P- AVP (pg/ml)
Placebo 0.20 ± 0.15 0.20 ± 0.15 0.20 ± 0.20  
Tolvaptan 0.70 ± 0.45 0.70 ± 0.55 0.70 ± 0.60
p (Wilcoxon’s signed rank test, between) <0.001 <0.001 <0.001
  1. Data are shown as mean with ± SD or medians with ± interquartile range. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as between subject factor. Post-hoc Bonferoni test (*) was used for comparison of infusion period 90–150 min vs baseline and post infusion period 150–210 vs baseline. Paired t-test or Wilcoxon signed rank test was used for comparison between treatment group at baseline vs during infusion period 90–150 minu, and at baseline vs post infusion period 150 – 210 min. *p < 0.05; **p < 0.001;***p < 0.0001.